vector
securities
international
said
friday
upgraded
rating
targeted
genetics
corp
buy
neutral
cited
price
weakness
said
company
cystic
fibrosis
gene
therapy
program
generated
strong
potential
partners
appears
company
form
major
partnership
world
class
biopharma
firm
early
quarter
vector
said
near
term
milestones
drive
targeted
genetics
shares
6
price
level
vector
added
targeted
genetics
1/4
3-1/4
reuters
chicago
newsdesk
312
408-8787
